SF3B2 and colorectal carcinoma: As expected, in CRC cell lines and CRC organoids in vitro as well as subcutaneous xenograft models in vivo, pladienolide B demonstrated strong and selective antiproliferative activities towards CRC with high RNF6 expression, confirming that pharmacological blockade of RNF6-SF3B2 axis is a potential approach for suppressing CRC progression.